WEX to resume development of Tectin for cancer-related pain

By Elaine Rigoli

Tampa, Fla., Sept. 6 - WEX Pharmaceuticals, Inc. said the Biologics and Genetic Therapies Directorate of Health Canada has approved the company's request to resume the clinical trials for Tectin - the company's analgesic that contains tetrodotoxin, a natural substance found in the puffer fish.

This authorization was granted after Health Canada reviewed the results of the re-analysis of the company's double-blind, placebo-controlled (WEX-014) and the open-label continuation (WEX-014OL) trials presented by the company at a preclinical trial application meeting.

The Vancouver-based drug-discovery company said it will map out the development steps with the authorities to further evidence the drug's efficacy in cancer-related pain.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.